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Behçet’s Disease and Pregnancy
Gökçe Işıl Kurmuş and Erol Koç
Abstract
Behçet’s disease (BD) is a rare, chronic, multisystemic, vasculitic disease of 
unknown etiology. BD is characterized by recurrent oral and genital ulcers and 
ocular inflammation. This systemic vasculitis may also involve the joints, skin, 
vascular, gastrointestinal, urogenital, and central nervous system and is associated 
with hypercoagulability. Disease onset is commonly around the third decade of life 
and has a higher prevalence along the ancient “silk route.” Because the disease is 
often diagnosed in women of childbearing age, disease activity during pregnancy 
and any adverse effect on obstetric and neonatal outcomes deserve special atten-
tion. Previous retrospective studies have demonstrated that BD activity usually 
regresses in pregnancy because of the immunomodulatory effects of both estrogen 
and progesterone. Furthermore, previous reports from different countries indicate 
that the disease course of BD during pregnancy may vary from patient to patient 
and even during different pregnancies in the same woman. In this chapter, we 
emphasize the course of the BD and pregnancy outcomes.
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1. Introduction
Behçet’s disease (BD) is a rare, chronic, relapsing, multisystemic, and inflamma-
tory disorder involving the oral and genital mucosa, eyes, joints, gastrointestinal, 
urogenital, vascular, and central nervous system [1–3]. It commonly occurs between 
the ages of 18 and 40, mainly affects young men, and tends to affect individuals with 
“silk road” bloodlines (corresponding the ancient route between the Mediterranean, 
the Middle East, and the Far East) [2–5]. Although the etiopathogenesis of the 
disease still remains unknown, it has been hypothesized as a genetic predisposition 
determined by the human leucocyte antigen-B51 (HLA-B51) allele. Infectious agents 
such as herpes simplex virus 1 or Streptococcus species may play a role as pathogenic 
triggers in genetically predisposed individuals [4–12]. BD is characterized by histo-
pathologic vasculitic changes and thrombogenicity, which are common to all involved 
organs. Vessels of all sizes are affected, both in the arterial and venous systems, with 
venous involvement being more common than arterial involvement [1, 4].
Most BD patients at disease onset are in their reproductive ages. Since about 
half of the patients with this disease are women, BD activity during pregnancy, and 
obstetric and neonatal outcomes must be carefully researched. Any possible interac-
tion between this two multisystemic condition deserves special attention [1, 13, 14]. 
Very little is known about the influence of BD and pregnancy to date. In few anecdotal 
case reports and retrospective small sample studies, both remissions and flares during 
pregnancy have been reported, and the effect of the disease on pregnancy remained 
unclear [1–4, 13–22]. Based on previous studies, it can be concluded that disease activ-
ity usually regresses during pregnancy.
Different Aspects of Behçet’s Disease
2
2. Discussion
The variability in the activity of BD in different pregnancies may be associ-
ated with various immunomodulatory effects of estrogen and progesterone, 
which are significantly elevated during pregnancy. Pregnancy has been associ-
ated with suppression of humoral and cellular-mediated immunological func-
tions [23–26]. Estrogen may have anti-inflammatory actions by stimulating 
anti-inflammatory interleukin (IL)-10 production and counteracting the effects 
of IL-12, antigen-presenting capacity, and tumor necrosis factor [26–32]. 
Progesterone may induce the inhibition of T cell, macrophage, and natural killer 
cell activity during pregnancy [24, 28–31]. Progesterone can enhance both Th2 
cell polarization and Treg cell production [24–30]. Oh et al. reported the case 
of a young woman who experienced flares of BD during every premenstrual 
period [33]. This condition dramatically improved when the patient received oral 
contraceptive therapy. As a result, it is suggested that steady-state levels of estro-
gen and progesterone, during pregnancy or oral contraceptive treatment, may 
play a role in the suppression of BD exacerbations. Krause et al. reported that 
neutrophil functions such as chemotaxis and adherence were depressed during 
pregnancy, and this was associated with an improvement in autoimmune diseases 
[34]. It may be the reason for the reduced number of BD flares during pregnancy, 
because excessive neutrophil activation has been involved in BD pathogenesis. 
Ferraro et al. reported an almost complete absence of autoantibodies during 
pregnancy in a recent study [35].
In an extensive review of the literature, both remissions and exacerbations 
of BD were investigated during pregnancy, and it has been reported that disease 
activity may differ between pregnancies in the same women [13, 15, 35–47]. The 
current data is limited to retrospective studies and individual case reports. Hurt 
et al. reported a case of severe, recurrent, oral, and genital mucosal ulcerations and 
iridocyclitis during the second trimester of pregnancy [46]. Madkour and Kudwah 
reported prolonged mucocutaneous and articular exacerbations during pregnancy 
and during treatment with oral contraceptive pills, in four women with BD [47]. 
Farrag et al. described one case of severe vaginal and cervical ulcers in the third 
trimester of pregnancy, treated by prednisolone [48]. Bang et al. reported on 20 
pregnancies with BD, in which 12 became exacerbated [15]. The most common 
lesions were oral and genital ulcers in Bang’s study. Similarly, in the series of Gürler 
and Erdi, exacerbations were observed in most of the cases [49].
In recent studies, the main symptoms during BD flares were oral ulceration and 
genital ulceration, followed by skin lesions and ocular inflammation; no neurological 
or gastrointestinal symptoms were observed during pregnancy [3, 13, 36, 38, 46–48]. 
The most serious manifestations of the exacerbation were vascular complications 
such as Budd-Chiari syndrome and deep vein thrombosis (DVT) [3, 36, 49]. Some 
case reports that have been reported are severe disease flares such as DVT with 
nephrotic syndrome, superior vena cava thrombosis, dural sinus thrombosis, or 
intracardiac thrombosis [16, 19, 50, 51].
Conversely, some authors reported remissions during pregnancy in BD 
patients. Hamza et al. studied 21 pregnancies in eight women with BD and found 
remissions in 12 pregnancies [38]. In this study mainly genital ulcers were seen 
in nine flares during the last trimester, despite systemic corticotherapy. Marsal 
et al. studied 25 pregnancies in 10 women and reported 23 remissions and only 
2 flares [36]. Chajek and Fainaro reported a woman with persistent BD who had 
remissions only during her pregnancies over a 20-year follow-up [43]. Ferraro 
et al. and Larsson and Baum reported two similar cases with complete remissions 
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during pregnancy with a flare after delivery [35, 45]. In a recent study, Uzun et al. 
reported on 44 pregnancies in 28 women and found remission rate to be 52.3%, 
while exacerbation rate was 27.3% [13]. In this study in nine pregnancies, there 
were no changes in the clinical course of BD.
In a single retrospective study by Noel et al., the authors compared the fre-
quencies of BD exacerbations in the periods before gestation with the rate during 
pregnancy [3]. They observed that the annual incidence of BD flares per patient was 
lower during pregnancy than during the nonobstetric period. In most series there 
was no association between the pregnant woman’s ages, the age at onset of Behçet’s 
disease, and the course of the disease during pregnancy. Noel et al. found that the 
shorter duration of BD prior to conception had the higher rate of exacerbation. In 
addition, they investigated that the treatment with colchicine was associated with 
lesser exacerbations during pregnancy. On the other hand, Seyyahi et al. considered 
that since BD becomes less severe with the passage of time, it is also expected to see 
less flares with long disease duration [52]. Moreover, patients who were treated only 
with colchicine had probably a milder disease, and hence, they experienced less 
flares during pregnancy.
In a review Ben-Chetrit reported the rate of complications ranges between 4 
and 20% of pregnancies in eight different studies [14]. In these studies only Marsal 
et al., Jadaon et al., and Iskender et al. compared their study groups with healthy 
controls [1, 2, 36]. Marsal et al. reported no significant differences in the incidence 
of maternal and fetal complications (abortions, congenital abnormalities, perinatal 
death, etc.) between BD patients and healthy controls [36]. In the series of Iskender 
et al., the frequencies of stillbirth, preeclampsia, preterm delivery, and cesarean 
deliveries did not differ between groups [1]. Jadaon et al. reported the highest rate 
of complications (20%) of these studies and significantly more than control groups 
[2]. The authors considered that especially the higher rate of miscarriage, but 
also the elevated pregnancy complication rate, may be explained by the vasculitic 
process underlying the pathogenesis of BD, as well as by hypercoagulability during 
pregnancy in BD patients. There was no difference of the neonatal outcomes such as 
intrauterine growth restriction, congenital abnormalities, neonatal weight, APGAR 
score at 1 and 5 min, respiratory distress syndrome, intraventricular hemorrhage, 
convulsions, prematurity, and perinatal death between the study and control 
groups [2]. In the reports by Noel et al. and Nadzi et al., the rate of complications 
was similar (16–19%) among their BD pregnant patients [3, 53]. In these studies, 
the high rate of miscarriages and the high number of deliveries by cesarean section 
were reported. Noel et al. observed a significant association between a history of 
DVT in BD and the risk of obstetric complications (miscarriages and cesarean deliv-
eries) [3]. They found that the previous venous involvement due to BD increased 
obstetric complications, as previously suggested by Jadaon et al. [2]. All of such 
patients in their cohort had experienced prior DVT, and two had associated cerebral 
venous thrombosis. The main obstetric complications were miscarriages for these 
patients. The authors considered that there was a link between venous thrombosis 
and the risk of default in trophoblast implantation [3]. They suggested that the 
antiphospholipid syndrome must be ruled out. The risk of fetal loss in BD is, how-
ever, lower than the risk in antiphospholipid syndrome [54]. Jadaon et al. thought 
that the presence of anti-endothelial cell antibodies in the sera of patients with 
BD and impaired function of vascular endothelial cells may explain the high rate 
of miscarriages and pregnancy complications in BD patients [2, 55, 56]. However, 
these observations were not reported by other retrospective studies. In addition, the 
outcome of pregnancies varied even during different pregnancies in the same BD 
patient, suggesting that it is not invariably related to BD.
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Jadaon et al. observed the rate of BD patients in which patients who went into 
remission was significantly higher than the number of patients who had exac-
erbations in the postpartum period [2]. In this case control study, it was shown 
that patients, who went into remission or exacerbation during pregnancy, tend 
to continue in the same direction after delivery. When the rate of remissions and 
exacerbations during pregnancy and postpartum period was compared, they found 
that the difference between the rate of remissions and exacerbations during preg-
nancy and postpartum for each of the women was not significant. They reported 
that there was no difference in disease activity during pregnancy and postpartum 
between HLAB51-positive and HLAB51-negative BD patients. In this study the 
number of pregnancies that were conceived under treatment was as follows: 29 
of 77 patients with corticosteroids, 1 with colchicine, 1 with insulin, and 5 with 
heparin [2]. Hamza et al. reported exacerbations of BD in nine pregnancies despite 
corticosteroid treatment (10–15 mg/day) but no significant obstetric complications 
[38]. In a 20 case series reported by Marsal et al., 3 patients with corticosteroids, 1 
patient with colchicine, and 1 patient with cyclosporine all discontinued the treat-
ments at the onset of the pregnancy, due to concerns regarding adverse effects [36].
Many of the medications used in the treatment of BD are safe to use during 
pregnancy. These include corticosteroids, cyclosporine, and azathioprine. There 
is now growing evidence to suggest that colchicine is also safe to use in pregnancy, 
and previous concerns about associations with fetal chromosomal abnormalities 
have not been proven. The question of whether colchicine treatment is safe during 
pregnancy is important, because colchicine crosses the human placenta [3]. Despite 
the antimitotic effects of colchicine, the safety of this drug during pregnancy 
was recently assessed in a prospective comparative cohort study in which 238 
colchicine-exposed pregnancies were followed up [57]. Increase in teratogenicity or 
congenital abnormalities was not observed. This finding is consistent with previous 
reports and underlines the safety of colchicine during pregnancy [58]. There is no 
agreement on the therapy of deep venous thrombosis and PE in BD [16]. Systemic 
anticoagulation with conventional agents including aspirin and low-molecular-
weight heparin (LMWH) is usually applied because of hypercoagulability of 
pregnancy, but lack of response or recurrence may occur if immunosuppressive 
therapy is not continued [59].
New agents such as the anti-TNF-alpha monoclonal antibodies such as inflix-
imab and etanercept have been used to treat inflammatory conditions in pregnancy 
and appear safe. There is no report that exposure to TNF inhibitors is toxic to 
the developing fetus. However, due to the limitations of available data and lack 
of controlled trials, there is not sufficient evidence to demonstrate the safety of 
the fetus exposed to TNF inhibitors during pregnancy. Moreover, the long-term 
safety of the infant is uncertain. If possible, discontinuation of the TNF inhibitor 
is desirable during pregnancy. If it appears to be necessary to use a TNF inhibitor 
to control the disease activity during mid and late pregnancy, then inoculations of 
live vaccine after birth pose a problem [20, 60]. It was reported that an infant born 
from a patient with Crohn’s disease and exposed to infliximab during pregnancy 
died due to disseminated BCG because of a live vaccine received at 3 months of age 
[61]. Therefore, any infant exposed to anti-TNF monoclonal antibody in the uterus 
should be protected from the administration of a live vaccine until at least 6 months 
from birth or until the drug disappears from the serum [20]. Data on more than 300 
pregnancies showed that infliximab carries low fetal risk during conception and 
the first two trimesters but suggests considering discontinuation in the early third 
trimester to minimize late fetal exposure to the risk of neonatal immunosuppres-
sion [62]. However, if treatment needs to be continued to keep the BD controlled, 
then the advantages probably outweigh the theoretical disadvantages. In a case 
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report, a 30-year-old woman diagnosed with BD at 12 weeks of pregnancy was 
successfully treated with infliximab, 5 mg/kg repeated dosages after 18 weeks of 
pregnancy, with improvement in all symptoms and normal full-term delivery [21]. 
A 36-year-old Japanese woman with intestinal BD (a recurrent ileocecal ulcer) was 
treated with adalimumab [20]. In this case, infliximab treatment showed second-
ary failure, so infliximab was switched to adalimumab. After the third injection 
of adalimumab, the patient was unexpectedly 4-week pregnant. Adalimumab was 
continued until the 20 weeks of pregnancy. Remission of the disease activity during 
pregnancy, the disappearance of ileocecal ulcer after delivery was reported, and the 
birth was uneventful in this case. It was also reported that adalimumab was detected 
in the umbilical blood after 119 days from the last infusion. The placental transition 
and timing of neonatal vaccination should be considered in cases of pregnancy with 
TNF antibody therapy [20].
Thalidomide is an effective treatment of oral and genital ulceration in BD but 
should never be used in pregnancy or in the absence of effective contraception 
because of its teratogenicity. Mycophenolate mofetil may also cause fetal malforma-
tions and should ideally be discontinued prior to pregnancy. It may sometimes be 
replaced with azathioprine. Disease-modifying drugs such as low-dose methotrex-
ate and cytotoxic drugs such as chlorambucil and cyclophosphamide used in BD 
to treat inflammation of the brain and eye should also be avoided when planning a 
pregnancy as these medications may cause fetal abnormalities. These drugs should 
be discontinued at least 3 months prior to conception and alternative safe medica-
tions commenced if necessary [63].
During lactation the risk of taking medication that may suppress neonatal 
immune system must be balanced against the many benefits that breast milk 
confers and the risk of disease relapsing if medication is not taken. Prednisolone 
and azathioprine are safe to use during lactation, and only low concentrations 
of cyclosporine are transferred to the breast milk, so these may be safe as well. 
Similarly colchicine, which is secreted into breast milk, has had no adverse side 
effects associated with its use in lactation [57]. Other agents such as infliximab and 
etanercept are not thought to be secreted in breast milk, but there are as yet no data 
on whether these drugs are safe to use in lactation [20, 21].
3. Conclusions
It seems that pregnancy in general does not have harmful effects on the natural 
course of BD at all, though the limited number of cases reported and the lack of 
prospective studies. When the data from all the published series were analyzed, it 
has been considered that more than 50% of BD patients will improve remission dur-
ing pregnancy. However, the BD activity usually regresses during pregnancy, and it 
is more recommended that due to the diverse course of the disease among different 
patients with the various clinical presentations and organ involvement, the disease 
course will differ. In some patients, the disease will go into remission, and in others, 
it will exacerbate during pregnancy. The variability in BD course during pregnancy 
is not limited to different patients. Even in the same patient, in one pregnancy, the 
disease may remain stable, while in a subsequent one, the disease exacerbates. There 
was no association between the number of pregnancy and the natural course of the 
disease.
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